CK0803

Phase 1Biologic

CCellenkos, Inc.

CK0803 is one of 40 biologic programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Amyotrophic Lateral SclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

55 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Vimpat

Enablex

Nourianz

Kyowa Kirin Co., Ltd.

Approved

—4

Bosulif

PPrism Pharmaceuticals

Approved

1 5

Qalsody

Biogen

Approved

3 6

Rocephin

CConrado Roberto Hoffmann Filho

Approved

—7

Transderm Scop

BBaxter Healthcare Corporation

Approved

—8

Rapamune

PPrism Pharmaceuticals

Avodart

Mirapex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Amyotrophic Lateral Sclerosis

NCT05695521

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

Regulatory T Cells for Amyotrophic Lateral Sclerosis

Active, not recruiting·CCellenkos, Inc.·Phase 1·NCT05695521·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CK0803. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CK0803 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CK0803. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cellenkos, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCellenkos, Inc.

CK0803

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

References

Drug Info

Quick Facts

Related News